Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 8/20 | 0.39 |
| ▸ | METAP1 | P53582 | 6/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8174538 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL1164582 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL27882015 | 0.97 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL18213891 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL14763884 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL8645598 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL112149 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL805601 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL112148 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL28012631 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256562-A1 | Transdermal Delivery System | IMPAX LABORATORIES, LLC | 2018-09-13 | — | — | US | claimed |
| EP-3349737-A1 | TRANSDERMAL DELIVERY SYSTEM | Amneal Pharmaceuticals LLC (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048595-A1 | TRANSDERMAL DELIVERY SYSTEM | AMNEAL PHARMACEUTICALS LLC (US) | 2017-03-23 | — | — | WO | claimed |
| WO-2012161790-A1 | CONCENTRATED CHEMICAL COMPOSITION AND METHOD FOR REMOVING PHOTORESIST DURING MICROELECTRIC FABRICATION | MOORE JOHN (US) | 2012-11-29 | — | — | WO | claimed |
| US-20110253171-A1 | Chemical Composition and Methods for Removing Epoxy-Based Photoimageable Coatings Utilized In Microelectronic Fabrication | MOORE JOHN | 2011-10-20 | — | — | US | claimed |
| EP-0211667-B1 | RADIATION-SENSITIVE RESIN COMPOSITION | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1992-03-11 | — | — | EP | claimed |
| EP-0457367-A1 | Radiation-sensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1991-11-21 | — | — | EP | claimed |
| EP-0211667-A2 | Radiation-sensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1987-02-25 | — | — | EP | claimed |
| CN-122004216-A | Herbicide composition containing cyclohexene diketone lactic acid oxime ether derivative and application thereof | 郑州手性药物研究院有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260098114-A1 | LARGE PARTICLE SIZE FLUOROPOLYMER LATEX PREPARATION | ARKEMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260098161-A1 | LARGE PARTICLE SIZE FUNCTIONALIZED FLUOROPOLYMER LATEX PREPARATION | ARKEMA INC. (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4594434-A2 | LARGE PARTICLE SIZE FUNCTIONALIZED FLUOROPOLYMER LATEX PREPARATION | Arkema, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4594433-A2 | LARGE PARTICLE SIZE FLUOROPOLYMER LATEX PREPARATION | Arkema, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250164873-A1 | PHOTORESIST COMPOSITION AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-05-22 | — | — | US | disclosed |
| US-4137237-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4070475-A | THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-24 | — | — | US | disclosed |
| US-4025527-A | H-2 HISTAMINE RECEPTOR INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-24 | — | — | US | disclosed |
| US-4024271-A | INHIBITORS OF HISTAMINE ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-3950333-A | HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098161-A1 | LARGE PARTICLE SIZE FUNCTIONALIZED FLUOROPOLYMER LATEX PREPARATION | F12, PF4, F11 | ALDH1A1 2500/4885LMNA 357/4885HSD17B10 4684/4885 |
| US-20260098114-A1 | LARGE PARTICLE SIZE FLUOROPOLYMER LATEX PREPARATION | LASP1, LAS1L, F12 | ALDH1A1 2861/4885LMNA 364/4885HSD17B10 4632/4885 |
| US-20180256562-A1 | Transdermal Delivery System | SLC6A2, SLC10A1, OPRL1 | ALDH1A1 3519/4885LMNA 2529/4885HSD17B10 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.